This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Astex Pharmaceuticals Announces Oral Presentation Of SGI-110 AML Data At The European Cancer Congress

DUBLIN, Calif., Sept. 30, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that detailed clinical responses and biomarkers data of relapsed/refractory AML (r/r AML) patients treated in the Phase 1 part of the SGI-110-01 study were presented at the European Cancer Congress (ECC: ECCO-ESMO-ESTRO) in Amsterdam, Netherlands.

The data were presented in the Oral Papers Session of Hematological Malignancies on Saturday, September 28, by Professor Jean-Pierre Issa, MD, Director, Fels Institute for Cancer and Molecular Biology, Temple University, Philadelphia, PA. The presentation title was: "Study of the correlation of baseline biomarkers and DNA demethylation to clinical responses in a Phase 1/2 randomized study of SGI-110, a novel subcutaneous hypomethylating agent, in the treatment of relapsed/refractory acute myeloid leukemia."

The presentation showed that of the 50 heavily pre-treated Phase 1 AML patients with LINE-1 DNA methylation data, there were 5 Complete Responses, or 10% (2 CRs, 1 CRp, and 2 CRi). There were no responders in the 31 patients (0%) who had LINE-1 DNA demethylation of less than 10% after treatment, while all 5 responders were in the 19 patients (26%) who had LINE-1 demethylation of at least 10% (0 vs. 26%, p <0.01). The median duration of response was approximately 4 months (114 days), and two responders had complete responses for approximately 1 and 1.5 years (350, and 558 days respectively). Two of the 5 responders had prior hypomethylating agent treatment, and two patients had prior bone marrow transplants. Patients with low baseline DNMT-3b expression seemed to correlate with better LINE-1 demethylation and response. Other baseline biomarkers -- Cytidine deaminase (CDA), deoxycytidine kinase (dCK) and micro-RNA 29b -- did not seem to correlate with either LINE-1 demethylation or clinical response.

The first data from the Phase 2 AML patients in both r/r AML and treatment-naïve elderly AML were submitted for presentation at the upcoming 2013 American Society of Hematology Annual Meeting, December 7-10, New Orleans, LA. Top line data on the complete cohort of r/r AML patients, and 17 treatment-naïve elderly AML patients were released on August 28, 2013.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs